Holdings

Lynx1 Capital Management LP

As of Sep 30, 2026, Lynx1 Capital Management LP reported 27 positions worth US$331M. Largest: Cullinan Therapeutics, Inc., Stoke Therapeutics, Inc. and C4 Therapeutics, Inc. What it bought and sold, with each filing.

CompanySharesValue as reportedChangeAs of
Cullinan Therapeutics, Inc.8.96MUS$138Mno changeSep 30, 2026
Stoke Therapeutics, Inc.3.9MUS$101M−142KSep 30, 2026
C4 Therapeutics, Inc.7.53MUS$25.1M+204KSep 30, 2026
Precision BioSciences, Inc.2.76MUS$17.3M+1.81MSep 30, 2026
Agios Pharmaceuticals, Inc.473KUS$15.7M−2.94MSep 30, 2026
Korro Bio, Inc.1.54MUS$15.3M+6,684Sep 30, 2026
Neuphoria Therapeutics Inc.875KUS$3.12Mno changeSep 30, 2026
Passage Bio, Inc.674KUS$3.03Mno changeSep 30, 2026
TScan Therapeutics, Inc.8.02MUS$2.52Mno changeSep 30, 2026
Kazia Therapeutics Ltd226KUS$2.17MnewSep 30, 2026